Roth Capital analyst Richard Baldry downgraded Forian to Neutral from Buy with a price target of $2.10, down from $5. The company reported good Q3 results but the shares offer little upside given the majority of shareholders have chosen to take Forian private at $2.10 per share, the analyst tells investors in a research note.
